
|Articles|May 18, 2011
WaveTec Vision secures additional financing
WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.
Advertisement
Aliso Viejo, CA-WaveTec Vision has secured $15.9 million in Series D financing from existing and new investors.
The company will use the funds to expand commercialization of its intraoperative wavefront aberrometer (ORange), demonstrate further the clinical efficacy of the technology, and increase its infrastructure, said Tom Frinzi, WaveTec chief executive officer.
The Series D financing was led by existing investor Versant Ventures, with participation from existing investors Accuitive Medical Ventures and De Novo Ventures. New investor Gund Investment Corporation also participated in the funding.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
5





















